2023-02-24 ·Medicilon Events
Medicilon Assists CGeneTech's Oral Hypoglycemic DPP-4 Inhibitor, New Drug Application (NDA) Accepted
CGeneTech submitted the DPP-4 inhibitor, for the treatment of type 2 diabetes, to the NMPA for approval. Medicilon, as a partner of CGeneTech, provided comprehensive preclinical research services in compliance with GLP regulations, including pharmacodynamic research, pharmacokinetic research and safety evaluation, as well as Phase I clinical bioanalysis to facilitate its efficient and high-quality R&D.
More